There are 5 available EGFR TKIs for the treatment of patients with EGFR-mutant lung cancers: gefitinib (Iressa), erlotinib (Tarceva), afatinib (Gilotrif), dacomitinib (Vizimpro), and osimertinib.
Brittany Lovely
Advertisement
Articles by Brittany Lovely
Meaningful improvements in outcomes with immunotherapy in recent years are finally starting to change the tide for the first-line treatment of patients with small-cell lung cancer.
Advertisement
Latest Updated Articles
How Immunotherapy is Changing the Treatment of Small Cell Lung CancerPublished: February 11th 2020 | Updated:
The Role of Tyrosine Kinase Inhibitors in Non–small Cell Lung CancerPublished: February 13th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
2
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
3
Disparities in Continuous Glucose Monitor Prescriptions by Language Preference Among Adults With Type 2 Diabetes
4
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
5
